BAVIS_1170x120_1-20

Jeff Needham

Perrigo announces FDA approval, launch for the store brand equivalent of Imodium Multi-Symptom Relief

Perrigo announces FDA approval, launch for the store brand equivalent of Imodium Multi-Symptom Relief

DUBLIN — Perrigo Company announced that it has received final approval from the U.S. Food & Drug administration for the store brand over-the-counter (OTC) equivalent of Imodium Multi-Symptom Relief (loperamide hydrochloride and simethicone tablets, 2 mg/125 mg). This product will be packaged and marketed as store brands or retailer ‘own label’ brands and will provide consumers

Perrigo readies store-brand Mucinex DM Maximum Strength

Perrigo readies store-brand Mucinex DM Maximum Strength

DUBLIN, Ireland — Perrigo Co. has been cleared by the Food and Drug Administration to market over-the-counter guaifenesin and dextromethorphan hydrobromide extended-release tablets 1200 mg/60 mg, an expectorant and cough suppressant. Perrigo said Wednesday that its guaifenesin and dextromethorphan ER tablets are an OTC generic version of Mucinex DM Maximum Strength tablets from Reckitt Benckiser. Plans call

Perrigo licenses meth-resistant tech for PSE products

Perrigo licenses meth-resistant tech for PSE products

DUBLIN, Ireland — Perrigo Co. plc is bringing in methamphetamine-blocking capability for pseudoephedrine (PSE) products. On Tuesday, Perrigo said it has entered an exclusive licensing agreement with St. Louis-based Highland Pharmaceuticals for its Tarex meth-blocking technology. The deal also includes the distribution rights of Zephrex-D, the pseudoephedrine nasal decongestant marketed by Highland’s Westport Pharmaceuticals unit.